MedPath

Optical Coherence Tomography Versus Intravascular Ultrasound Guided Percutaneous Coronary Intervention

Not Applicable
Active, not recruiting
Conditions
Coronary Vessels
Interventions
Procedure: PCI
Registration Number
NCT03394079
Lead Sponsor
Seung-Jung Park
Brief Summary

The primary aim of this study is to compare the clinical efficacy and safety of OCT-guided(optical coherence tomography (OCT)-guided) and IVUS-guided(Intravascular ultrasound (IVUS)-guided) strategies in patients undergoing Percutaneous coronary intervention (PCI) with contemporary drug-eluting stents (DES) or drug-coated balloons (only for in-stent restenosis) for significant obstructive Coronary artery disease (CAD).

The investigators hypothesize that OCT-guided PCI is non-inferior to IVUS-guided PCI with respect to primary end point of target-vessel failure (cardiac death, target-vessel myocardial infarction \[MI\], or ischemia-driven target-vessel revascularization \[TVR\]) at 1 year after randomization.

Detailed Description

Not available

Recruitment & Eligibility

Status
ACTIVE_NOT_RECRUITING
Sex
All
Target Recruitment
2008
Inclusion Criteria
  • Men or women at least 19 years of age
  • Subjects with obstructive CAD undergoing PCI with contemporary DES or drug-coated balloons (only for in-stent restenosis) under intracoronary imaging guidance.
  • The patient or guardian agrees to the study protocol and the schedule of clinical follow-up and provides informed, written consent, as approved by the appropriate Institutional Review Board/Ethical Committee of the respective clinical site.
Exclusion Criteria
  • ST-elevation myocardial infarction
  • Severe renal dysfunction (eGFR <30 ml/min/1.73 m2 or serum creatinine level >1.5 mg/dl), unless patient is on renal replacement therapy.
  • Cardiogenic shock or decompensated heart failure with severe LV dysfunction (LVEF) < 30%
  • Life expectancy < 1 year for any non-cardiac or cardiac causes
  • Any lesion characteristics resulting in the expected inability to deliver the IVUS or OCT catheter to the lesion pre- and post-PCI (eg, moderate or severe vessel calcification or tortuosity)
  • Any clinically significant abnormality identified at the screening visit, physical examination, laboratory tests, or electrocardiogram which, in the judgment of the Investigator, would preclude safe completion of the study
  • Unwillingness or inability to comply with the procedures described in this protocol

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
OCT-guidedPCI-
IVUS-guidedPCI-
Primary Outcome Measures
NameTimeMethod
Rate of target vessel failure1 year

A composite of cardiac death, target-vessel MI or ischemia-driven TVR) at 1 year after randomization.

A composite endpoint is an endpoint that is a combination of multiple clinical endpoints. An event is considered to have occurred if any one of several different events is observed.

Secondary Outcome Measures
NameTimeMethod
Rate of stent thrombosis1, and 5 years

Stent thrombosis is defined according to according to the definite or probable criteria of the Academic Research Consortium.

Rate of target-lesion failure1, and 5 years

Cardiac death, target-vessel myocardial infarction or ischemia-driven target-lesion revascularization

Rate of angiographic or imaging-based device success1 day

Patient- or lesion-level analysis.

Angiographic device success is defined as successful PCI at the intended target-lesion with final in-stent residual stenosis of less than 30% by quantitative coronary angiography (QCA). Imaging-based device success is defined as successful PCI at the intended target-lesion, which fulfills the optimal criterial for stent implantation by IVUS or OCT.

Rate of cardiac Death1, and 5 years
Rate of death1, and 5 years

cardiac, vascular, non-cardiovascular death

Rate of repeat revascularization1, and 5 years

Any, target-lesion or non-target-lesion, target-vessel or non-target-vessel, ischemia-driven or non-ischemia-driven.

Rate of any hospitalization1, and 5 years

Cardiac or non-cardiac causes.

Rate of myocardial infarction1, and 5 years

periprocedural or spontaneous, Q-wave or non-Q-wave.

Rate of target vessel myocardial infarction1, and 5 years
Rate of ischemia-driven target vessel revascularization1, and 5 years
Rate of contrast-induced acute kidney injury3 days

Contrast-induced nephropathy is defined as either a greater than 25% increase of serum creatinine or an absolute increase in serum creatinine of 0.5 mg/dl within 72 hours after PCI.

Rate of stroke1, and 5 years

Stroke is defined as focal loss of neurologic function caused by an ischemic or hemorrhagic event, with residual symptoms lasting at least 24 hours or leading to death.

Rate of bleeding events1, and 5 years

Life-threatening or disabling, major bleeding, or minor.

Bleeding events are assessed according to the Bleeding Academic Research Consortium (BARC) criteria.

Rate of procedural complications requiring active intervention that were related to PCI or intracoronary imaging devices1 day

Procedural complications (e.g., angiographic dissection of at least type B, coronary perforation, vasospasm, thrombus formation, air embolization, slow flow or no reflow, distal embolization, acute closure, ventricular arrhythmia, cardiac tamponade, or cardiogenic shock) requiring active interventions (prolonged balloon inflations, additional stenting required, thrombus aspiration, pericardiocentesis, cardioversion, or use of mechanical circulatory support devices), which are related to PCI procedures or intravascular imaging evaluation.

Trial Locations

Locations (9)

Korea University Anam Hospital

🇰🇷

Seoul, Korea, Republic of

Kyung hee university hospital

🇰🇷

Seoul, Korea, Republic of

Keimyung University Dongsan Medical Center

🇰🇷

Daegu, Korea, Republic of

Konyang University Hospital

🇰🇷

Daejeon, Korea, Republic of

Chonnam National University Hospital

🇰🇷

Gwangju, Korea, Republic of

Pusan National University Hospital

🇰🇷

Pusan, Korea, Republic of

Asan Medical Hospital

🇰🇷

Seoul, Korea, Republic of

Gangnam Severance Hospital

🇰🇷

Seoul, Korea, Republic of

Chung-Ang university hospital

🇰🇷

Seoul, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath